Efficient in vitro and in vivo activity of glyco-engineered plant-produced rabies monoclonal antibodies E559 and 62-71-3

PLoS ONE

Volumn 11, Issue 7, 2016, Pages

  Tsekoa, Tsepo Lebiletsa ^a   Lotter Stark, Therese ^a   Buthelezi, Sindisiwe ^a   Chakauya, Ereck ^a   Stoychev, Stoyan H ^a   Sabeta, Claude ^b   Shumba, Wonderful ^b   Phahladira, Baby ^b   Hume, Steve ^c   Morton, Josh ^c   Rupprecht, Charles E ^d   Steinkellner, Herta ^e   Pauly, Michael ^c   Zeitlin, Larry ^c   Whaley, Kevin ^c   Chikwamba, Rachel ^a  

^a DSI CSIR Nanotechnology Innovation Centre   (South Africa)

^b ONDERSTEPOORT VETERINARY INSTITUTE   (South Africa)

^c Mapp Biopharmaceutical ^*  (United States)

^d WISTAR INSTITUTE   (United States)

^e UNIVERSITY OF NATURAL RESOURCES AND LIFE SCIENCES   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 62 71 3; MONOCLONAL ANTIBODY E559; RABIES IMMUNOGLOBULIN; UNCLASSIFIED DRUG; RABIES VACCINE; RECOMBINANT PROTEIN; VIRUS ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ARTICLE; CALORIMETRY; CONCENTRATION RESPONSE; CONTROLLED STUDY; FEMALE; GLYCOSYLATION; HAMSTER; IN VITRO STUDY; IN VIVO STUDY; MASS SPECTROMETRY; NICOTIANA BENTHAMIANA; NONHUMAN; PLANT BIOTECHNOLOGY; PROTEIN ASSEMBLY; PROTEIN EXPRESSION; RABIES; RABIES VIRUS; THERMOSTABILITY; VIRUS NEUTRALIZATION; VIRUS TITRATION; AGROBACTERIUM TUMEFACIENS; ANIMAL; BIOSYNTHESIS; CHEMISTRY; DRUG EFFECTS; GENE EXPRESSION; GENE VECTOR; GENETICS; GROWTH, DEVELOPMENT AND AGING; IMMUNOLOGY; MESOCRICETUS; METABOLISM; MOLECULAR CLONING; MORTALITY; PASSIVE IMMUNIZATION; PATHOGENICITY; SERODIAGNOSIS; SURVIVAL ANALYSIS; TOBACCO; TRANSGENIC PLANT; VIROLOGY;

AGROBACTERIUM TUMEFACIENS; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, VIRAL; CLONING, MOLECULAR; FEMALE; GENE EXPRESSION; GENETIC VECTORS; IMMUNIZATION, PASSIVE; MESOCRICETUS; NEUTRALIZATION TESTS; PLANTS, GENETICALLY MODIFIED; RABIES; RABIES VACCINES; RABIES VIRUS; RECOMBINANT PROTEINS; SURVIVAL ANALYSIS; TOBACCO;

EID: 84979284156     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0159313     Document Type: Article

References (25)

1. Shantavasinkul P, Wilde H. Postexposure prophylaxis for rabies in resource-limited/poor countries. Advances in virus research. 2011; 79:291-307. doi: 10.1016/B978-0-12-387040-7.00013-5 PMID: 21601051
2. Manning SE, Rupprecht CE, Fishbein D, Hanlon CA, Lumlertdacha B, Guerra M, et al. Human rabies prevention - United States, 2008: recommendations of the Advisory Committee on Immunization Practices. MMWR Recommendations and reports: Morbidity and mortality weekly report Recommendations and reports / Centers for Disease Control. 2008 May 23; 57(RR-3):1-28.
3. Knobel D, Cleaveland S, Coleman P. Re-evaluating the burden of rabies in Africa and Asia. Bull World Health Organ 2005; 83:931-42.
4. Hampson K, Coudeville L, Lembo T, Sambo M, Kieffer A, Attlan M, et al. Global Alliance for Rabies Control Partners for Rabies Prevention. Estimating the global burden of endemic canine rabies. PLoS Negl Trop Dis. 2015 Apr 16; 9(4):e0003709. eCollection 2015 Apr.
5. Erratum Hampson K, Coudeville L, Lembo T, Sambo M, Kieffer A, Attlan M, et al. Global Alliance for Rabies Control Partners for Rabies Prevention. Estimating the global burden of endemic canine rabies. in: PLoS Negl Trop Dis. 2015 May;9(5):e0003786. doi: 10.1371/journal.pntd.0003709 PMID: 25881058
6. Satpathy DM, Sahu T, Behera TR. Equine rabies immunoglobulin: a study on its clinical safety. Journal of the Indian Medical Association. 2005 Apr; 103(4):238, 41-2. PMID: 16173435
7. Muller T, Dietzschold B, Ertl H, Fooks AR, Freuling C, Fehlner-Gardiner C, et al. Development of a mouse monoclonal antibody cocktail for post-exposure rabies prophylaxis in humans. PLoS Negl Trop Dis. 2009; 3(11):e542. doi: 10.1371/journal.pntd.0000542 PMID: 19888334
8. Both L, Banyard AC, van Dolleweerd C, Horton DL, Ma JK, Fooks AR. Passive immunity in the prevention of rabies. The Lancet Infectious diseases. 2012 May; 12(5):397-407. doi: 10.1016/S1473-3099(11)70340-1 PMID: 22541629
9. Smith TG, Wu X, Franka R, Rupprecht CE. Design of future rabies biologics and antiviral drugs. Advances in virus research. 2011; 79:345-63. doi: 10.1016/B978-0-12-387040-7.00016-0 PMID: 21601054
10. Kuzmina N, Kuzmin I, Ellison J, Rupprecht C. Conservation of binding epitopes for monoclonal antibodies on the rabies virus glycoprotein. J Antivir Antiretrovir. 2013; 5:039-46.
11. Strasser R, Stadlmann J, Schahs M, Stiegler G, Quendler H, Mach L, et al. Generation of glyco-engineered Nicotiana benthamiana for the production of monoclonal antibodies with a homogeneous human-like N-glycan structure. Plant biotechnology journal. 2008 May; 6(4):392-402. doi: 10.1111/j.1467-7652.2008.00330.x PMID: 18346095
12. Giritch A, Marillonnet S, Engler C, van Eldik G, Botterman J, Klimyuk V, et al. Rapid high-yield expression of full-size IgG antibodies in plants coinfected with noncompeting viral vectors. Proceedings of the National Academy of Sciences of the United States of America. 2006 Oct 3; 103(40):14701-6. PMID: 16973752
13. Both L, van Dolleweerd C, Wright E, Banyard AC, Bulmer-Thomas B, Selden D, et al. Production, characterization, and antigen specificity of recombinant 62-71-3, a candidate monoclonal antibody for rabies prophylaxis in humans. FASEB journal: official publication of the Federation of American Societies for Experimental Biology. 2013 May; 27(5):2055-65.
14. van Dolleweerd CJ, Teh AY, Banyard AC, Both L, Lotter-Stark HC, Tsekoa T, et al. Engineering, expression in transgenic plants and characterisation of E559, a rabies virus-neutralising monoclonal antibody. The Journal of infectious diseases. 2014 Jul 15; 210(2):200-8. doi: 10.1093/infdis/jiu085 PMID: 24511101
15. Daugherty AL, Mrsny RJ. Formulation and delivery issues for monoclonal antibody therapeutics. Adv Drug Deliv Rev. 2006 Aug 7; 58(5-6):686-706. PMID: 16839640
16. Forthal DN1, Gach JS, Landucci G, Jez J, Strasser R, Kunert R, Steinkellner H. Fc-glycosylation influences Fcγ receptor binding and cell-mediated anti-HIV activity of monoclonal antibody 2G12. Immunol. 2010 Dec 1; 185(11):6876-82.
17. Hiatt A, Bohorova N, Bohorov O, Goodman C, Kim D, Pauly MH, Velasco J, Whaley KJ, Piedra PA, Gilbert BE, Zeitlin L. Glycan variants of a respiratory syncytial virus antibody with enhanced effector function and in vivo efficacy. Proc Natl Acad Sci U S A. 2014 Apr 22; 111(16):5992-7. doi: 10.1073/pnas.1402458111 PMID: 24711420
18. Pettitt J, Zeitlin L, Kim do H, Working C, Johnson JC, Bohorov O, Bratcher B, Hiatt E, Hume SD, Johnson AK, Morton J, Pauly MH, Whaley KJ, Ingram MF, Zovanyi A, Heinrich M, Piper A, Zelko J, Olinger GG. Therapeutic intervention of Ebola virus infection in rhesus macaques with the MB-003 monoclonal antibody cocktail. Sci Transl Med. 2013 Aug 21; 5(199):199ra113. doi: 10.1126/scitranslmed.3006608 PMID: 23966302
19. Gerdes CA, Nicolini VG, Herter S, van Puijenbroek E, Lang S, Roemmele M, Moessner E, Freytag O, Friess T, Ries CH, Bossenmaier B, Mueller HJ, Umaña P. GA201 (RG7160): a novel, humanized, glycoengineered anti-EGFR antibody with enhanced ADCC and superior in vivo efficacy compared with cetuximab. Clin Cancer Res. 2013 Mar 1; 19(5):1126-38. doi: 10.1158/1078-0432.CCR-12-0989 PMID: 23209031
20. Junttila TT, Parsons K, Olsson C, Lu Y, Xin Y, Theriault J, Crocker L, Pabonan O, Baginski T, Meng G, Totpal K, Kelley RF, Sliwkowski MX Superior in vivo efficacy of afucosylated trastuzumab in the treatment of HER2-amplified breast cancer.Cancer Res. 2010 Jun 1; 70(11):4481-9. doi: 10.1158/0008-5472.CAN-09-3704 PMID: 20484044
21. Stadlmann J, Pabst M, Kolarich D, Kunert R, Altmann F. Analysis of immunoglobulin glycosylation by LC-ESI-MS of glycopeptides and oligosaccharides. Proteomics. 2008 Jul; 8(14):2858-71. doi: 10.1002/pmic.200700968 PMID: 18655055
22. Doi E, Jirgensons B. Circular dichroism studies on the acid denaturation of gamma-immunoglobulin G and its fragments. Biochemistry. 1970 Mar 3; 9(5):1066-73. PMID: 5418708
23. Liu Y, Huang L, Dong S. Electrochemical catalysis and thermal stability characterization of laccase-carbon nanotubes-ionic liquid nanocomposite modified graphite electrode. Biosens Bioelectron. 2007 Aug 30; 23(1):35-41. PMID: 17459687
24. Wang W, Singh S, Zeng DL, King K, Nema S. Antibody structure, instability, and formulation. J Pharm Sci. 2007 Jan; 96(1):1-26. PMID: 16998873
25. Rybicki EP, Chikwamba R, Koch M, Rhodes JI, Groenewald JH. Plant-made therapeutics: an emerging platform in South Africa. Biotechnology advances. 2012 Mar-Apr; 30(2):449-59. doi: 10.1016/j.biotechadv.2011.07.014 PMID: 21839824